Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1)
J Parenter Enteral Nutr
Hector Perez, a board-certified bariatric surgeon, believes the interest in these probiotics could also be "an aftereffect of the success of GLP-1 drugs, which have now brought public focus on gut microbiome and weight loss." He notes that more people are beginning to connect that metabolism goes beyond calories and may be shaped by gut health
Second, GHK-Cus effectiveness depends on systemic distribution, not local concentration
US$ 26.33
US$ 26.22
US$ 29.55
US$ 23.43
US$ 20.35
US$ 21.44
